• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AGC (TSE:5201), What Is Behind The Fresh Attention?

    Simply Wall St·09/20/2026 11:19:35
    Listen to the news

    AGC (TSE:5201) has drawn fresh attention after recent trading left the share price around ¥5,646. Returns are down over the past month and past 3 months, despite positive annual revenue and net income growth.

    Over the past year, AGC’s share price return has risen 8.06% year to date. Meanwhile, the 1 year total shareholder return of 22.13% and a softer 90 day share price return, down 25.87%, suggest earlier momentum has cooled and recent sentiment has become more cautious.

    Scan how AGC compares with other industrials by lining up its recent pullback against a hand picked group of list of solid balance sheet and fundamentals (21 results)

    AGC’s pullback sits awkwardly next to growing revenue and net income. Are you looking at a business that has changed, or a mood swing in the market that valuation work can clarify next?

    Most Popular Narrative: 13% Undervalued

    AGC’s most followed valuation narrative points to a fair value of ¥6,516, compared with the recent close around ¥5,646, which frames the recent pullback as a possible disconnect between price and underlying forecasts.

    Expanded production capacity in Southeast Asia, especially in Chemicals (chlor-alkali, PVC), is described as positioning AGC to capture greater market share in regions with structural supply constraints, supporting higher top-line growth and scale-driven margin expansion. Structural reforms and the strategic exit from loss-making U.S. biopharmaceutical operations are expected to eliminate a major drag on profits, while refocusing Life Science on high-growth, single-use bag (SUB) technologies is expected to restore segment profitability and drive new growth from 2026 onward, directly benefitting net income.

    See why 4 investors see AGC as 13% undervalued.

    Result: Fair Value of ¥6,516 (UNDERVALUED)

    Still, the AGC narrative could be knocked off course if weak demand and pricing pressure in Asia persist, or if Life Science losses drag on longer than expected.

    Find out about the key risks to this AGC narrative.

    Next Steps

    Curious whether the recent cool down around AGC is a risk, a reward, or a bit of both? Take a few minutes to review the numbers, then weigh the balance of 3 key rewards and 1 important warning sign

    Looking for more AGC investment ideas?

    Ready to widen your watchlist beyond AGC and spot fresh opportunities before they move? Use the Simply Wall Street Screener to surface focused ideas that fit your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.